Month: September 2020

ENSPRYNG lowered relapse severity in double-blind periods of SAkura Phase III studies.Pooled data from SAkura open-label extension (OLE) studies support continued effect of ENSPRYNG reducing risk of relapse in the longer termOngoing data continues to show a favourable safety profile for ENSPRYNGENSPRYNG was recently approved by the U.S. Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSDBasel, 10 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued...

LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors on its innovative HIV, Hepatitis B and Oncology platforms at the H.C. Wainwright 22nd Annual Global Investment Conference.Enochian BioSciences’ Executive Vice Chair, Dr. Mark Dybul, will be presenting to a live virtual audience on Tuesday, September 15, 2020 at 2:00 pm Eastern, and will be participating in one-on-one meetings with investors who are registered to attend the conference. A link to the live and archived webcast may be accessed on Enochian’s website under the Investors/Media section in Events and Presentations.More information on the conference may be found at...

ORION CORPORATION PRESS RELEASE 10 SEPTEMBER 2020 at 7.30 EEST                      New England Journal of Medicine publishes final overall survival data for darolutamide showing treatment significantly extends life in men with non-metastatic prostate cancerMen with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003)Darolutamide significantly improved all other secondary endpoints, including times to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE)The safety profile at final analysis remains consistent with the earlier analysis; overall, the rate of adverse events was comparable to ADT aloneThe New England Journal...

ORION OYJ LEHDISTÖTIEDOTE 10.9.2020 klo 7.30                      New England Journal of Medicine -lehti julkaisi darolutamidin lopulliset kokonaiselinaikaa koskevat tulokset, jotka osoittavat hoidon pidentävän merkitsevästi etäpesäkkeetöntä kastraatioresistenttiä eturauhassyöpää sairastavien miesten elinaikaaDarolutamidin ja tavanomaisen hormonaalisen hoidon (androgeenideprivaatioterapia, ADT) yhdistelmä pidensi merkitsevästi kokonaiselinaikaa verrattuna lumelääkkeen ja ADT:n yhdistelmään (HR=0,69, 95 % CI 0,53-0,88; p=0,003) etäpesäkkeetöntä kastraatioresistenttiä eturauhassyöpää (nmCRPC) sairastavilla miehilläDarolutamidi saavutti myös muut toissijaiset muuttujat ja pidensi muun muassa merkitsevästi aikaa hoidon aloittamisesta solunsalpaajahoidon aloittamiseen sekä ensimmäiseen oireiseen luustohaittaanDarolutamidin turvallisuusprofiili...

STEINHAUSEN, Switzerland, Sept. 09, 2020 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) announced today the final results of the previously announced offers (the “Exchange Offers”) by Transocean Inc., its wholly-owned subsidiary (together with Transocean Ltd., “Transocean”), to exchange the existing notes set forth in the table below (collectively, the “Existing Notes”) for 11.50% Senior Guaranteed Notes due 2027 (the “New 2027 Senior Guaranteed Notes”) to be issued by Transocean Inc. The Exchange Offers were made pursuant to the Exchange Offer Memorandum and Consent Solicitation Statement, dated August 10, 2020 (as supplemented, the “Exchange Offer Memorandum”).The Exchange Offers expired at 5:00 p.m., New York City time, on September 9, 2020 (the “Expiration Time”). According to information received from D.F. King & Co., Inc.,...

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $40.00 per share. Albireo’s gross proceeds from this offering are expected to be $160 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Albireo. The offering is expected to close on or about September 14, 2020, subject...

CINCINNATI, Sept. 09, 2020 (GLOBE NEWSWIRE) — LSI Industries Inc. (NASDAQ: LYTS, or the “Company”) a leading U.S. based manufacturer of indoor/outdoor lighting and graphics solutions, today said that Jim Clark, the Company’s President and Chief Executive Officer, and Jim Galeese, Chief Financial Officer, will make a virtual presentation to investors during H.C. Wainwright & Company’s 22nd Annual Global Investment Conference on September 14, 2020.  During the presentation, LSI will discuss its growth strategy, which includes vertical market expansion, an additional focus on end-customers, expanding its existing services business, and inorganic growth.In addition to the presentation, Mr. Clark and Mr. Galeese will meet virtually with investors during a series of one-on-one breakout meetings.  Conference registration information...

VANCOUVER, British Columbia, Sept. 09, 2020 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) reports on Red Chris drill results which continue to validate the East zone high grade pod. Partial results from drill hole RC634, located in the East zone, returned 394 metres grading 1.6 g/t gold and 0.86% copper starting at 650 metres, and  include a  166 metre interval grading 3.0 g/t gold and 1.5% copper from 806 metres down the hole.Newcrest Mining Limited Managing Director and Chief Executive Officer, Sandeep Biswas, said “Drilling results at Red Chris have returned 166 metres grading 3.0 g/t gold and 1.5% copper, which is significantly higher than we would expect to find in porphyry systems. Red Chris’ results also confirm the presence of multiple discrete high grade pods of mineralization within the East...

TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) — iSIGN Media Solutions Inc. (“iSIGN” or “Company”) (TSX-V: ISD) (OTC: ISDSF), a leading provider of interactive mobile proximity marketing and public security alert solutions announced in accordance with Ontario Instrument 51-502, Temporary Exemption from Certain Corporate Finance Requirements, of the Ontario Securities Commission (the “Exemption Order”), which was adopted for the purpose of providing certain filing and other relief to issuers in light of the challenges posted by the COVID-19 pandemic, that it has completed the filing of certain of its continuous disclosure documents.The filing of the Company’s audited annual financial statements, the related management’s discussion and analysis and certifications for the fiscal year ended April 30, 2020 (the “Required Annual Filings”) completes...

AUSTIN, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has been invited to present at the 22nd H. C. Wainwright Annual Global Investment Conference, which is being held virtually on September 14-16, 2020.Plus Therapeutics, Inc management is scheduled to present on Tuesday, September 15 at 4.00 p.m. eastern time, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at https://wsw.com/webcast/hcw7/pstv/1644325.To receive additional information, request an invitation or to schedule a one-on-one meeting, please click on this link – meeting attendance link.About Plus Therapeutics, Inc.Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio...